Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues
Eli Lilly has splashed up to $3.8 billion on an infectious disease pipeline, acquiring Curevo, LimmaTech Biologics and Vaccine Company to extend its shopping sp...
Eli Lilly has splashed up to $3.8 billion on an infectious disease pipeline, acquiring Curevo, LimmaTech Biologics and Vaccine Company to extend its shopping spree into viral and bacterial pathogen R&D.